RCKT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RCKT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Rocket Pharmaceuticals's shares outstanding for the quarter that ended in Dec. 2024 was 106.45 Mil.
Rocket Pharmaceuticals's quarterly shares outstanding increased from Sep. 2024 (91.12 Mil) to Dec. 2024 (106.45 Mil). It means Rocket Pharmaceuticals issued new shares from Sep. 2024 to Dec. 2024 .
Rocket Pharmaceuticals's annual shares outstanding increased from Dec. 2023 (90.28 Mil) to Dec. 2024 (106.45 Mil). It means Rocket Pharmaceuticals issued new shares from Dec. 2023 to Dec. 2024 .
The historical data trend for Rocket Pharmaceuticals's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rocket Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Shares Outstanding (EOP) | Get a 7-Day Free Trial |
![]() |
![]() |
61.00 | 64.51 | 79.12 | 90.28 | 106.45 |
Rocket Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Shares Outstanding (EOP) | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
90.28 | 90.65 | 90.96 | 91.12 | 106.45 |
For the Biotechnology subindustry, Rocket Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Rocket Pharmaceuticals's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
Rocket Pharmaceuticals (NAS:RCKT) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Thank you for viewing the detailed overview of Rocket Pharmaceuticals's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.
Jonathan David Schwartz | officer: Chief Medical Officer | 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016 |
Martin Wilson | officer: General Counsel | C/O TELIGENT, INC., 105 LINCOLN AVENUE, BUENA NJ 08310 |
Gaurav Shah | director, officer: See Remarks | 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016 |
John Militello | officer: See Remarks | C/O IMMUNE PHARMACEUTICALS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016 |
Kinnari Patel | officer: Chief Operating Officer | 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016 |
Mark Andrew White | officer: Chief Medical Officer | C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY NJ 08512 |
David P Southwell | director, officer: See Remarks | C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421 |
Gotham Makker | director | 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016 |
Rtw Investments, Lp | 10 percent owner | 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
Fady Ibraham Malik | director | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Carlos Garcia-parada | officer: Chief Financial Officer | C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE SUITE 7530, NEW YORK NY 10118 |
Elisabeth Bjork | director | C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10116 |
Kamran Alam | officer: SVP - Finance & PFO | 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118 |
Naveen Yalamanchi | director | 412 WEST 15TH STREET, 9TH FLOOR, NEW YORK NY 10019 |
Brian Batchelder | officer: See Remarks | 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016 |
From GuruFocus
By Business Wire • 06-28-2024
By Business Wire • 11-12-2024
By GuruFocus Research • 02-08-2024
By Business Wire • 11-07-2024
By Business Wire • 01-02-2025
By Business Wire • 11-08-2024
By Business Wire • 11-26-2024
By Business Wire • 09-17-2024
By Business Wire • 08-05-2024
By Business Wire • 09-10-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.